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Abstract
Background: Neuroinflammation is thought to play an important role in the pathogenesis of ICU-acquired
delirium, but the association between inflammatory and brain-specific proteins and ICU delirium is poor. We
investigated whether or not serial determinations of markers may improve this association.
Methods: Critically ill patients with a high risk of ICU delirium and with an ICU length of stay of at least 6 days
were included in the study. Blood was drawn on days 1, 2, 4 and 6 after ICU admission and analyzed for different
markers of inflammation and several brain proteins. Differences in courses over time prior to and following the
onset of delirium and absolute differences over time were analyzed in patients with and without delirium using
repeated measurement analysis of variance. In addition, a cross-sectional analysis of levels of these markers before
the first onset of delirium was performed.
Results: Fifty patients were included in this study. In the longitudinal analysis, there were no differences in the
levels of any of the markers immediately prior to and following the onset of delirium, but overall, median levels of
adiponectin (9019 (IQR 5776–15,442) vs. 6148 (IQR 4447–8742) ng/ml, p = 0.05) were significantly higher in patients
with delirium compared to patients without delirium. In the cross-sectional analysis, median levels of the brain
protein Tau (90 (IQR 46–224) vs. 31 (IQR 31–52) pg/ml, p = 0.009) and the ratio Tau/amyloid β1–42 (1.42 ((IQR 0.9–2.57)
vs. 0.68 (IQR 0.54–0.96), p = 0.003) were significantly higher in patients with hypoactive delirium compared to patients
without. Levels of neopterin (111 (IQR 37–111) vs. 29 (IQR 16–64) mmol/l, p = 0.004) and IL-10 (28 (IQR 12–39)
vs. 9 (IQR 4–12) pg/ml, p = 0.001) were significantly higher in patients with hypoactive delirium compared to
patients with mixed-type delirium.
Conclusions: While there are differences in markers (adiponectin and several brain proteins) between patients
with and without delirium, the development of delirium is not preceded by a change in the biomarker
profile of inflammatory markers or brain proteins. Patients with hypoactive delirium account for the observed
differences in biomarkers.
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Background
ICU-acquired delirium is a frequently occurring problem
in critically ill patients and is independently associated
with a myriad of negative short-term and long-term out-
comes [1–3]. While recent research shows that many
risk factors are associated with the development of delir-
ium, its pathogenesis is still incompletely understood
and involves a combination of predisposing and precipi-
tating factors [4]. In recent years, the inflammatory re-
sponse as a trigger for brain damage and its clinical
substrate, delirium, has been a subject of investigation.
This neuro-inflammatory hypothesis assumes a systemic
inflammatory response, which stimulates release of cyto-
kines in the brain by microglial cells. The cerebral cyto-
kine release leads to a spectrum of clinical symptoms,
ranging from a relatively mild sickness behavior syn-
drome to full-blown delirium [5, 6]. Indeed, associations
between levels of pro-inflammatory markers and the
presence of delirium have been found in ICU and non-
ICU patients [7–10]. Also serum levels of other bio-
markers involved in the inflammatory response, such as
neopterin and monocyte chemoattractant protein-1
(MCP-1) are found in higher concentrations in patients
with delirium [11, 12]. Interestingly, markers of brain
damage have also been associated with delirium [9, 13, 14].
Levels of pro-inflammatory and anti-inflammatory
cytokines and adiponectin are also associated with
delirium in ICU patients [9, 10]. Since the levels of
biomarkers and the development of delirium may
change over time, serial measurements of biomarkers
may further elucidate the interplay between inflamma-
tion and neuronal injury. However, up to now, only a
limited number of studies with a time-series design have
been performed in ICU patients. There appear to be
higher levels of IL-6 in patients with delirium and an as-
sociation between S-100B concentrations and duration
of delirium [15, 16]. However, only a limited number of
biomarkers or a limited number of time points have
been analyzed. To gain more insight into the prediction
and development of delirium per se, the aim of our
study therefore was to determine whether levels of
inflammatory biomarkers, proteins, and brain proteins,
follow a different course in patients with delirium com-
pared to controls, before and after the actual develop-
ment of delirium. Additionally, a cross-sectional analysis
of these markers prior to the first occurrence of delirium
was performed, thereby discriminating between the sub-
types of delirium.
Methods
Study design
This biomarker study was part of the “Dynamic Light
Application to reduce ICU-acquired delirium” (DLA)
study, ClinicalTrials.gov number NCT 01274819), which
was a single-center randomized controlled trial, pub-
lished elsewhere [17]. In this study no difference in any
measured outcome was found between the intervention
and the control group. The study was approved by the
regional medical ethical committee (registration number
M392 NL 34780.028.10, Medisch Ethische Toetsing
Onderzoek bij Patiënten en Proefpersonen (METOPP),
Tilburg, the Netherlands). A preplanned longitudinal
case-control subgroup analysis of biomarkers in patients
with a high risk of developing delirium in the ICU was
part of the original protocol.
Patients and procedures
Inclusion and exclusion criteria for the DLA study have
been reported previously [17]. Between 2011 and 2013 a
total of 734 patients, who were not suffering from
delirium at the time of inclusion, were included in the
DLA study. For our biomarker sub-study we planned to
evaluate approximately 200 patients with a high risk of
delirium. Patients were therefore eligible if they had pre-
dicted risk of delirium in the ICU > 40% using the vali-
dated PRE-DELIRIC model [18]. Since we wished to
investigate if there was a biomarker that showed an
increase just before the development of delirium, only
patients with a length of stay of at least 6 days were in-
cluded and patients that remained comatose during the
first 7 ICU days were excluded. For the same reason
patients who developed delirium after 6 days of ICU
admission were also excluded. Blood was drawn from an
indwelling arterial catheter on the morning after their
ICU admission at 0800 h (admission day = 1), and, at the
same time, on days 2, 4 and 6. Blood samples were centri-
fuged and plasma was stored at − 70 °C until analysis.
Delirium assessment
Delirium was assessed using the Confusion Assessment
Method for the ICU (CAM-ICU). This widely used and
validated instrument, which has good performance [19],
was performed at least three times per day as part of
normal care. During the study period, the quality of the
CAM-ICU assessments was tested bimonthly by expert
delirium nurses to check for inter-observer reliability,
which remained good during the study, with a mean
Cohen’s κ of 0.79 (n = 178). Patients were considered as
having delirium if the CAM-ICU was positive at least
once within the first 7 days of their ICU admission. De-
lirium was assessed on a daily basis; if at least one
CAM-ICU screening was positive on any day, this was
considered to be a “delirium day”. It was then deter-
mined if there was a peak in biomarkers just before the
onset of delirium. Importantly, in the setting of sedative
use, patients with only one positive CAM-ICU screening
during their admission, with a Richmond Agitation and
Sedation Scale (RASS) score of − 1/− 3, were considered
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to have rapidly reversible sedation-related delirium [20].
These patients were not considered as truly delirious pa-
tients. Patients who developed delirium after 6 days in
the ICU and patients who were comatose during the
measurement period (defined as a persistent RASS score
of − 4 or less) were excluded. In all patients the subtype
of delirium was defined by means of the RASS score ac-
cording to the Peterson criteria [21]; if the RASS was
persistently zero or less during the time that delirium
was present, this was considered to be hypoactive delir-
ium, if not directly related to the use of sedatives. If the
RASS was below and above zero during delirium, this
was considered to be mixed-type delirium, and patients
with delirium who consistently had a RASS above zero
were identified as having hyperactive delirium.
Biomarkers
Concentrations of the pro-inflammatory cytokines
tumor necrosis factor (TNF)-α, interleukin (IL)-6 and
IL-1β, anti-inflammatory cytokine IL-10 and the chemo-
tactic cytokine MCP-1 were determined in ethylenedi-
aminetetraacetic (EDTA)-anticoagulated plasma by a
simultaneous multiplex immunoassay, according to the
manufacturer’s instructions (Bio-Plex, BioRad, Hercules,
CA, USA). The lower detection limit for all cytokines
was 4 pg/mL. Concentrations of adiponectin, neopterin
and total tau-protein were determined in edta-
anticoagulated plasma using enzyme-linked immuno-
sorbent assay (ELISA), according to the manufacturer’s
instructions (R&D systems, Abingdon, UK, IBL inter-
national GmbH, Hamburg, Germany and Life technolo-
gies, Bleiswijk, The Netherlands). The lower limits of
detection were 390 ng/mL for adiponectin, 1.35 nmol/L
for neopterin and 31.25 pg/mL for Tau-protein. Levels
of adiponectin were corrected for the patient’s body
mass index. The brain-specific proteins full-length amyl-
oid β1–42 and 1–40 (Aβ1–42 and Aβ1–40) were determined
in EDTA plasma by using a simultaneous Luminex assay
(INNO-BIA plasma Aβ forms; Fujirebio, Gent, Belgium).
The lower limit of detection was 18 pg/mL for both
Aβ1–40 and Aβ 1–42.
Statistics
The course over time in levels of the markers was evalu-
ated prior to or following delirium occurrence. The day
of delirium occurrence was taken as a reference point,
and the days that blood was drawn (admission days 1, 2,
4 and 6) were recoded based on this time point. For
example, if delirium occurred on admission day 4
biomarkers were analyzed on time point t-3 (admission
day 1), t-2 (admission day 2), t (admission day 4) and t + 2
(admission day 6). For comparison with the control group,
the median day of delirium occurrence in the delirium
group (i.e. day 3) was used for the non-delirious patients.
This means that in these patients blood was drawn on t-2
(admission day 1), t-1 (admission day 2), t + 1 (admission
day 4) and t + 3 (admission day 6) (see Additional file 1).
A cross-sectional analysis of differences in levels of
biomarkers one day before occurrence of delirium was
performed. Average values of the biomarkers before the
first occurrence of delirium were calculated by taking
the exact value of the biomarker if it was taken on the
day before the first occurrence of delirium or by aver-
aging the value of the biomarker taken the day before
and on the day of the occurrence of delirium in case de-
lirium occurred on days that no blood was drawn for
analysis (i.e. day 3). For patients, that did not develop
delirium, the value of the biomarker on the day before
delirium occurred, on average in the delirium group,
was used. In cases where delirium was already present
on the day of the first time point, the value of that sam-
ple was used (Additional file 1).
Differences in baseline characteristics between delir-
ium and non-delirium patients were tested using the
chi-square (χ2) test for categorical variables and
Student’s t test or the Mann-Whitney U test for nor-
mally or non-normally distributed variables, respectively.
The relationship between the biomarker levels over time
and the presence of delirium was assessed using re-
peated measures analysis of variance (RM-ANOVA)
whereby the between-subject factor group delirium and
non-delirium was reported, and which was adjusted for
variables that were significantly different between
patients with and without delirium. Due to the fact that
the assumptions of homogeneity and sphericity were
violated, the Greenhouse-Geisser correction was used.
Since several biomarkers had a skewed distribution, the
biomarker data were log-transformed allowing us to
perform RM-ANOVA. Due to the exploratory nature of
the longitudinal part of this study no correction for
multiple testing was performed in order to increase the
sensitivity to detect differences between groups. Differ-
ences between non-delirium and the subtypes of
delirium and the biomarkers were tested using the
Mann-Whitney U test. All statistical analyses were per-
formed using SPSS version 22.
Results
Between July 2011 and September 2012, 187 patients in-
cluded in the DLA study who had a high risk of delirium
were evaluated for this study. Of these patients, 101
were discharged within 6 days of ICU admission and
therefore a total of 86 patients were included in this
study (see Fig. 1). Of these patients, 27 (31%) were in a
persistent coma during the first week, 6 patients (7.0%)
developed delirium after 6 days of ICU admission and in
3 patients (3.5%) blood was drawn on days other than
those scheduled. As a result, 50 patients were analyzed
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for this longitudinal study, with a mean age of 72 years
(± 10.3) of whom 36 patients (74%) were male (Table 1).
Delirium occurred in 35 patients (70%). Patients in the
delirium group were significantly older than non-
delirious patients (73 vs. 67 years, p = 0.03) but there
were no significant differences between the two groups
in baseline demographic characteristics, although more
patients tended to be admitted with sepsis in the
delirium group compared with the non-delirium group
(46% vs. 20%, p = 0.08).
Hypoactive delirium was present in 11 patients (31%),
mixed-type delirium in 23 patients (66%) and hyperactive
delirium in 1 patient (3%). There were no significant differ-
ences in ICU or hospital length of stay or in hospital mor-
tality between patients with and without delirium (Table 1).
Longitudinal analysis
The median day of development of delirium was day 3
(IQR 2–4) after ICU admission. There were no differ-
ences in the levels of the markers over the course over
time prior to the onset of delirium, or in the time course
following the onset of delirium between patients who
did or did not develop delirium (Table 2 and Fig. 2).
Over time, levels of adiponectin remained significantly
higher in patients with delirium compared to those with-
out delirium (Table 2 and Additional file 2). Within-
subject analysis showed that levels of IL-6, IL-10 and
MCP-1 decreased significantly over time in both groups,
but were not different between patients with and
without delirium. There were no significant differences
between groups in any of the other markers over time.
Fig. 1 Enrollment scheme: selection of patients for the current study; to enable serial sampling, only patients with an ICU length of stay of at
least 6 days were selected. DLA, dynamic light application
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Values of Tau-protein, Aβ1–40 and Aβ1–42 remained
stable during the measurement period: 178/200 (89%) of
the measurements of IL-1β, 126/200 (63%) of the mea-
surements of TNF-α and 48/200 (24%) of the measure-
ments of neopterin were below the detection limit.
Cross-sectional analysis
Patients with versus patients without delirium
In three patients, delirium occurred before the first
blood sampling and in these cases the first value of the
biomarkers was used for analysis. Since only one patient
was diagnosed with a hyperactive form of delirium, we
did not include this patient in the subgroup analysis. We
found no differences in levels of inflammatory or brain-
specific markers one day before the development of de-
lirium (see Table 3).
Differences between patients with subtypes of delirium and
patients without delirium
When differentiating between clinical subtypes of delir-
ium, levels of Tau-protein and the ratio of Tau/Aβ1–42
was significantly higher in the hypoactive delirium group
compared to the non-delirium group (median 90 (IQR
46–224) vs. 31.25 (IQR 31.25–52) pg/mL, p = 0.009 and
median 1.42 (IQR 0.90–2.57) vs. 0.69 (IQR 0.54–0.96),
p = 0.003, respectively; see Table 3). Additionally, in the
subgroup of patients with hypoactive delirium, levels of
neopterin and IL-10 were significantly higher than in
the mixed-type delirium group (median 111 (IQR 37–111)
vs. 29 (IQR 16–64) mg/L, p = 0.004 and median 28 (IQR
12–39) vs. 9 (IQR 4–12) pg/mL, p = 0.001).
Discussion
In this longitudinal case-control study we found that
levels of inflammatory and brain proteins did not follow
different courses in patients immediately prior to or fol-
lowing the occurrence of delirium compared to levels in
patients that did not develop delirium. However, levels
of adiponectin over time remained significantly higher in
patients with delirium compared to those without. In
the cross-sectional analysis, we found that in patients
with hypoactive delirium the levels of Tau and the ratio
of Tau/Aβ1–42 were significantly higher compared with
patients without delirium. Levels of neopterin and IL-10
were significantly higher compared to levels in patients
with mixed-type delirium.
Several studies in non-ICU patients identified levels of
IL-6 and IL-8 to be most strongly correlated with the
development of delirium [22, 23]. Because delirium is
also associated with neuronal damage, markers of neur-
onal damage were also found to be elevated in patients
with delirium [8, 13]. Since the exact time point at which
Table 1 Baseline characteristics of the study population
Delirium (n = 35) No delirium (n = 15) Differences (p value)
Age in years, mean (SD) 73 (9.9) 67 (10) 0.03
Male, n (%) 23 (66) 13 (87) 0.12
Admission type:
Surgical (%) 8 (23) 3 (20)
Medical (%) 26 (74) 10 (67) 0.35
Neurotrauma (%) 1 (3) 2 (13)
APACHE-II score (SD) 26 (7) 28 (9) 0.42
Sepsis (patients), n (%) 16 (46) 3 (20) 0.08
PRE-DELIRIC score (mean, SD) 78 (18) 74 (19) 0.45
History of cognitive disorder, n (%) 4 (11) 1 (7) 0.52
Diabetes mellitus, n (%) 5 (14) 1 (7) 0.41
COPD, n (%) 1 (3) 2 (13) 0.21
Acute kidney injury, n (%) 12 (34) 3 (20) 0.25
Cardiovascular disease, n (%) 1 (3) 1 (7) 0.51
Use of steroids, n (%) 18 (51) 8 (53) 0.57
Study arm (DLA), n (%) 19 (54) 8 (53) 0.6
Intubation, n (%) 31(89) 14(93) 0.52
Hours of mechanical ventilation, median (IQR) 158 (96–281) 194 (116–383) 0.58
LOS-ICU in days, median (IQR) 12 (10–19) 15 (9–24) 0.45
LOS-hospital in days, median (IQR) 30 (17–42) 35 (19–50) 0.79
Hospital mortality, n (%) 12 (34) 3 (20) 0.25
Simons et al. Critical Care  (2018) 22:137 Page 5 of 10
delirium occurs and its underlying pathophysiological
substrate are often unclear, different markers may be ele-
vated at different time points, based on the timing of the
primary insult and the kinetics of the specific biomarker
involved. This may explain why no single biomarker has
consistently demonstrated an association with delirium
across different patients groups and diseases with differ-
ent etiology. Also, theoretically, the accuracy of bio-
markers to predict the development of delirium might
be better just before delirium occurs. In our study we
explored the time course of several biomarkers on the
days prior to and following the occurrence of delirium.
While associations between many markers and delirium
have been investigated, including insulin-like growth
factor, S-100B, and genetic markers such as the ApoE
gene [24], we advanced on our earlier data [9] and se-
lected a relevant subset of pro-inflammatory and anti-
inflammatory markers, brain-specific proteins and new
promising markers in line with previous ICU studies.
Based on the neuro-inflammatory hypothesis [25], we
presumed that, especially before the occurrence, levels
of pro-inflammatory biomarkers might show higher
values in patient that develop delirium, which would
strengthen the direct association between (neuro)inflam-
mation and delirium. In contrast, no differences were
observed immediately before or after delirium occur-
rence, suggesting that higher circulating levels of inflam-
matory and brain-specific markers in critically ill
patients are merely markers of systemic disease severity,
which in itself may be associated with delirium. This
limits the potential, independent role of these bio-
markers in identifying those at high risk for developing
delirium as well as the early detection of delirium.
These findings are in contrast with previous biomarker
studies in delirious ICU patients, with a time-series de-
sign. Daily levels of IL-6 were determined in 77 critically
ill patients and higher levels of IL-6 were identified in
patients with acute brain failure [15]. Lack of informa-
tion on the exact time point at which delirium occurred
and the inclusion of comatose patients makes a direct
comparison with our study difficult. S-100B was mea-
sured on day 1 and 8 in another 63 critically ill delirious
patients [16]. Higher levels of S-100B were associated
with a longer duration of delirium, but no comparison
with non-delirious patients was made.
We found that levels of adiponectin over time
remained significantly higher in patients with delirium
patients compared to patients without delirium, which is
in concordance with a previous study in ICU patients
[10]. Adiponectin is a protein excreted exclusively by
adipocytes and it has insulin-sensitizing, vascular-
protective and anti-inflammatory properties. Due to its
effects on downregulation of the immune response and
low adiponectin levels in patients with sepsis, some advo-
cate therapeutic use of adiponectin in critically ill patients
[26]. Although its effect on the brain is still unclear, our
Table 2 Median levels (interquartile range) of biomarkers over time; p-values indicate the between-subject differences between
delirium and non-delirium groups
Delirium (n = 35) Non-delirium (n = 15)
Day 1 Day 2 Day 4 Day 6 Day 1 Day 2 Day 4 Day 6 p value
Inflammation
TNF a (pg/mL) 10 (4–16) 4 (4–16) 4.0 (4–16) 4.0 (4–16) 4.0 (4–16) 4.0 (4–16) 4.0 (4–16) 4.0 (4–16) 0.24
IL-6 (pg/mL) 250 (82–1300) 163 (51–365) 75 (33–130) 43 (26–77) 343 (39–1171) 52 (20–446) 23 (16–102) 14 (11–39) 0.29
IL-1 beta (pg/mL) 4 (4–8) 4 (4–8) 4 (4–8) 4 (4–8) 4 (4–8) 4 (4–4) 4 (4–5) 4 (4–4) 0.13
IL-10 (pg/mL) 12 (7–25) 12 (4–24) 9 (5–18) 7 (4–14) 21 (8–36) 11 (5–21) 8 (4–18) 7 (5–33) 0.82
Neopterin (mmol/L) 37 (18–91) 50 (19–99) 45 (21–111) 39 (22–101) 51 (19–111) 76 (23–111) 62 (28–111) 74 (28–111) 0.18
MCP-1 (pg/mL) 233
(141–642)
239
(97–630)
171
(101–369)
120
(74–263)
143
(56–645)
141
(67–575)
82
(26–180)
70
(33–95)
0.08
Adiponectin (ng/mL) 7821
(4421–13,910)
8986
(4775–12,880)
9737
(6169–15,416)
10,379
(6486–20,695)
6065
(3163–8466)
4927
(4345–8023)
6232
(4393–9457)
6404
(4880–11,550)
0.05
Brain
Aβ1–42 (pg/mL) 58 (46–77) 56 (42–79) 53 (41–64) 55 (38–68) 54 (46–86) 56 (44–88) 54 (39–79) 54 (43–62) 0.74
Aβ1–40 (pg/mL) 179
(164–247)
181
(155–280)
177
(146–243)
177
(146–246)
165
(135–232)
169
(125–212)
156
(125–238)
181
(128–257)
0.61
Ratio Aβ1–40/42 0.28
(0.24–0.36)
0.28
(0.23–0.32)
0.28
(0.23–0.35)
0.26
(0.22–0.36)
0.34
(0.25–0.38)
0.33
(0.27–0.46)
0.30
(0.27–0.43)
0.29
(0.25–0.34)
0.37
Tau-protein (pg/mL) 31.25
(31.25–59)
31.25
(31.25–120)
31.25
(31.25–101)
31.25
(31.25–87)
31.25
(31.25–52)
31.25
(31.25–69)
36
(31.25–63)
49 (31.25–73) 0.19
Ratio Tau/ Aβ1–42 0.68
(0.50–1.19)
0.83
(0.56–1.43)
0.90
(0.59–1.70)
0.89
(0.74–1.29)
0.68
(0.59–0.96)
0.71
(0.53–1.03)
0.80
(0.58–1.42)
0.88
(0.65–1.36)
0.20
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results intriguingly show that there is a positive associ-
ation between levels of adiponectin and delirium. We did
not confirm associations between levels of pro-
inflammatory biomarkers over time, especially IL-6 and
IL8, and delirium, even though delirious patients appeared
to have more sepsis (46% vs. 20%, p = 0.08), a condition
that has been associated with delirium [27]. Contradictory
findings in ICU and non-ICU patients in relation to inflam-
matory markers and the development of delirium may, in
addition to the timing of the sampling and the etiology of
Table 3 Cross-sectional analysis of biomarkers one day prior to clinical occurrence of delirium; data are expressed as median (IQR)
No delirium
(n = 15)
Delirium
(n = 35)
Hypoactive delirium
(n = 11)
Mixed delirium
(n = 23)
Hyperactive delirium
(n = 1)
Inflammation
TNF a (pg/mL) 4 (4–16) 4 (4–16) 4 (4–16) 4 (4–16) 4
IL-6 (pg/mL) 343 (39–1171) 212 (75–412) 234 (195–461) 109 (51–365) 981
IL-1 beta (pg/mL) 4 (4–6) 4 (4–8) 4 (4–8) 4 (4–8) 8
IL-10 (pg/mL) 19 (8–28) 12 (5–28) 28 (12–39)a 9 (4–12) 20
Neopterin (mmol/L) 51 (19–111) 36 (23–95) 111 (37–111)b 29 (16–64) 24
MCP-1 (pg/mL) 143 (56–620) 239 (117–547) 454 (141–596) 168 (90–350) 953
Adinopectin (ng/mL) 6065 (3163–8466) 7997 (4421–12,880) 7391 (3952–10,499) 7997 (5014–16,099) 8212
Brain
Aβ1–42 (pg/mL) 54 (46–86) 57 (46–70) 63 (45–81) 55 (46–67) 70
Aβ1–40 (pg/mL) 174 (135–227) 200 (152–272) 229 (200–274) 167 (142–247) 194
Ratio Aβ1–40/42 0.34 (0.25–0.4) 0.26 (0.23–0.35) 0.26 (0.19–0.31) 0.27 (0.23–0.38) 0.36
Tau-protein (pg/mL) 31.25 (31.25–52) 31.25 (31.25–101) 90 (46–224)c 31.25 (31.25–75) 31.25
Ratio tau/Aβ1–42 0.68 (0.54–0.96) 0.91 (0.51–1.48) 1.42 (0.9–2.57)
d 0.66 (0.5–1.36) 0.45
ap = 0.001 for the difference between hypoactive delirium and mixed-type delirium
bp = 0.004 for the difference between hypoactive delirium and mixed-type delirium
cp = 0.009 for the difference between hypoactive delirium and no delirium
dp = 0.003 for the difference between hypoactive delirium and no delirium
Fig. 2 Time course of median values of biomarkers before and after the occurrence of delirium. 0 denotes the day of first the occurrence of delirium
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the delirium, be due to the fact that the effects of a systemic
inflammatory response on the brain are also mediated by
the amount of neurodegeneration [25, 28] and large differ-
ences between patient groups are likely present. In our
study five patients had a history of cognitive disorders (four
(11%) in the delirium group and one (7%) in the non-
delirium group (p = 0.52)). These groups are too small to
come to a conclusion based on these numbers.
We found no differences between patients with and
without delirium in the levels of brain-specific proteins;
however, when evaluating the clinical subtypes of delir-
ium we found that levels of Tau protein and the ratio of
Tau/Aβ1–42 were significantly higher in the hypoactive
delirium group compared to the non-delirium group. A
previous study showed that several isoforms of Aβ are
associated with delirium in ICU patients without inflam-
mation, whereby the difference in levels of Tau and the
Tau/Aβ1–42 ratio between these groups approached stat-
istical significance [9]. Interestingly, we found a some-
what similar association in hypoactive delirium; however,
in the current study we did not differentiate between pa-
tients with and without inflammation. In recent years,
the impact of subtype of delirium on various measures
has been the subject of investigation. While the
hypoactive form appears to have a worse outcome in
terms of short-term and long-term mortality in ICU
patients [3, 29], much is still unclear, especially about
its association with the development of long-term
cognitive disturbances.
We found levels of neopterin and IL-10 before the
onset of delirium to be significantly higher in patients
with hypoactive delirium compared to patients with
mixed-type delirium. Neopterin, a chemotactic marker
of inflammation produced by monocytes and macro-
phages, was found to be elevated in cerebrospinal
fluid (CSF) and serum from patients with delirium
[11, 30]; however, its role in critically ill patients has
not previously been determined. The association
between IL-10 and ICU-acquired delirium has shown
conflicting results [9, 10], but up to now no discrim-
ination between subtypes of delirium has been made.
Higher values in hypoactive delirium would therefore
suggest another pathophysiological mechanism
compared to mixed-type delirium, but this is not
supported by the absence of a difference in other
inflammatory markers or by a difference in baseline
characteristics in the groups. Further studies are
necessary to clarify this potential association.
There are several limitations that need to be
addressed. First, we measured inflammatory and
brain-specific markers in peripheral blood and not in
CSF. Levels of these markers and their course over
time in CSF may therefore differ from those in serum
and there may even be an association between
markers measured in CSF and the occurrence of
delirium. Second, we judged patients with one posi-
tive CAM-ICU score in the setting of sedative use as
having rapid reversible sedation-related delirium [20]
and therefore these patients were considered as not
having delirium. While this judgment is still under
debate, this only concerned one patient and consider-
ing this patient as having delirium would not have
altered the outcomes. Third, we included a relatively
small number of patients in a mixed medical surgical
ICU, thereby possibly limiting generalization of the
findings. Additionally, we did not correct for multiple
testing in our statistical analysis, increasing the risk
of false-positive findings. Fourth, we used the median
day of delirium onset (day 3) in the non-delirium
group for comparison to the patients with delirium.
Since it is unknown at what time point the brain of
the non-delirious would be most susceptible to
delirium development, this time point was chosen in
concordance with previous research [9]. Fifth, we
used the CAM-ICU to detect delirium. While the
specificity of the CAM-ICU is high, the sensitivity in
daily practice can be rather low [31]. Nevertheless, we
used the CAM-ICU three times per day, which
reduces the chance of a false-negative finding in deli-
rious patients. Finally, we did not take into account
the long-term outcomes of our patients, so we cannot
definitively confirm our hypothesis of an association
between levels of biomarkers and long-term cognitive
impairment.
Conclusions
In this study in critically ill patients, patterns of the
levels of markers of inflammation or brain proteins did
not differ in delirious patients immediately prior to or
following the occurrence of delirium, compared to non-
delirious patients. These findings indicate that these
biomarkers are of limited value in the prediction of
delirium.
Levels of adiponectin over time remained significantly
higher in patients with delirium compared to those with-
out. Cross-sectional analysis of laboratory values
obtained just prior to the clinical occurrence of delirium
showed that serum levels of Tau protein and the ratio of
Tau/Aβ1–42 were significantly higher in patients with the
hypoactive form of delirium compared to patients with-
out delirium. Levels of neopterin and IL-10 were signifi-
cantly higher in hypoactive delirium compared to
mixed-type delirium. These findings suggest different
pathways in the development of these subtypes of
delirium and a possible association between the hypoac-
tive form of delirium and the development of cognitive
disorders. Further studies are warranted to explore this
relationship.
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Additional files
Additional file 1: Table provides an exact description of the time points
of the blood sampling relative to the day of delirium occurrence and the
calculation of the biomarker level one day before the onset of delirium.
“t” denotes day of delirium occurrence. For example, if delirium occurred
on day 2 (t), then blood sample 1 was drawn on day 1 (t-1), blood sample 2
on day 2 (t), blood sample 3 on day 4 (t + 2) and blood sample 4 on day 6
(t + 4). (PDF 72 kb)
Additional file 2: Levels of the biomarkers over time in delirious and
non-delirious patients, whereby values are expressed as medians. (PDF 185 kb)
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